13F Holdings
中文EN

IQV IQVIA HOLDINGS INC.

Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1478242 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.8%
TTM net income YoY8.7%
TTM EPS YoY13.1%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR7.7%

Margins

Gross margin33.1%
Operating margin12.8%
Net margin8.1%
FCF margin12.0%
EBITDA margin19.9%

Returns

ROE21.7%
ROA4.7%
ROIC (approx.)9.3%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets77.7%
Debt / equity2.41x
Current ratio0.83x
Interest coverage2.83x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$16.31B$15.40B$14.98B$14.41B$13.87B
Cost of revenue$10.88B$10.03B$9.74B$9.38B$9.23B
Gross profit$5.43B$5.38B$5.24B$5.03B$4.64B
SG&A expense$2.00B$1.99B$2.05B$2.07B$1.96B
Operating income$2.18B$2.20B$1.98B$1.80B$1.39B
Interest expense$729.00M$670.00M$672.00M$416.00M$375.00M
Pretax income$1.59B$1.67B$1.46B$1.36B$1.13B
Income tax$252.00M$301.00M$101.00M$260.00M$163.00M
Net income$1.36B$1.37B$1.36B$1.09B$966.00M
EBITDA$3.33B$3.32B$3.10B$2.93B$2.66B
EPS (basic)7.917.577.395.825.05
EPS (diluted)7.847.497.295.724.95
Weighted avg. shares (diluted)173.50M183.40M186.30M190.60M195.00M
Balance sheet
Cash & equivalents$1.98B$1.70B$1.38B$1.22B$1.37B
Short-term investments$161.00M$141.00M$120.00M$93.00M$111.00M
Receivables$3.40B$3.20B$3.38B$2.92B$2.55B
Current assets$6.25B$5.83B$5.60B$4.98B$4.76B
PP&E, net$533.00M$535.00M$523.00M$532.00M$497.00M
Goodwill$16.62B$14.71B$14.57B$13.92B$13.30B
Intangibles$4.96B$4.50B$4.84B$4.82B$4.94B
Total assets$29.94B$26.90B$26.68B$25.34B$24.69B
Current liabilities$8.34B$6.96B$6.49B$5.58B$5.24B
Short-term debt$1.84B$1.15B$718.00M$152.00M$91.00M
Long-term debt$13.88B$12.84B$12.96B$12.60B$12.03B
Total debt$15.72B$13.98B$13.67B$12.75B$12.12B
Total liabilities$23.31B$20.83B$20.57B$19.57B$18.65B
Shareholders' equity$6.50B$6.07B$6.11B$5.76B$6.04B
Net debt$13.74B$12.28B$12.30B$11.53B$10.76B
Shares outstanding169.60M176.10M181.50M185.70M190.60M
Cash flow statement
Operating cash flow$2.65B$2.72B$2.15B$2.26B$2.94B
Capital expenditure$603.00M$602.00M$649.00M$674.00M$640.00M
Free cash flow$2.05B$2.11B$1.50B$1.59B$2.30B
Investing cash flow-$2.31B-$1.44B-$1.60B-$2.01B-$2.10B
Financing cash flow-$150.00M-$878.00M-$382.00M-$329.00M-$1.24B
Depreciation & amortization$1.14B$1.11B$1.12B$1.13B$1.26B
Stock-based compensation$247.00M$206.00M$217.00M$194.00M$170.00M
Share buybacks$1.24B$1.35B$992.00M$1.17B$406.00M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.